LLY vs ZBH
Eli Lilly and Company vs Zimmer Biomet — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
68
Buy
VS
| Metric | LLY | ZBH |
|---|
| AI Score |
68
|
69
|
| Price |
$1,180.33
|
$100.62
|
| P/E Ratio |
39.54×
|
24.37×
|
| ROE |
77.8%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.0%
|
69.9%
|
| Debt / Equity |
1.62×
|
0.59×
|
| Dividend Yield |
0.6%
|
1.0%
|
| RSI (14) |
57.1
|
68.8
|
| Beta |
0.506
|
0.462
|
| Expected Upside |
+5.8%
|
+0.8%
|
AI Committee View
Current Innellis committee reasoning for LLY versus ZBH.
ZBH leads by 1 points.
ZBH scores 69/100 (Buy) versus LLY at 68/100 (Buy).
LLY Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical